NEW YORK, NY / ACCESSWIRE / February 16, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is covering InMed Pharmaceuticals Inc. (OTCQB: IMLFF). During 2016, ImMed achieved some significant milestones, including: induction of strong biopharmaceutical expertise in their senior management team, financial closures to fund continued drug/disease target identification, advanced analysis of existing datasets to ensure clinical development plans are accurate and positioned to maximize the likelihood for positive outcomes, validation and advancement of the manufacturing process, filing of provisional patents, and expanded scope of opportunities for cannabinoid-based products.
The company continues to focus on research into fundamental benefits of cannabinoid drugs to address high unmet medical needs, selective advancement of high-potential drug candidates, identification and retention of industry veterans to define and execute the present & future drug development programs in a time- and cost-effective manner, collaboration with biotech-savvy investor groups & exploration into the partnership potential of the various programs and assets.
Get InMed Pharmaceuticals full pipeline and company prospects in the FULL REPORT
(Copy and paste to your browser may be required to view the full report- http://bit.ly/2kA730w-IMLFF-Analyst)
InMed Pharmaceuticals Inc. is a pre-clinical stage biopharmaceutical company specializing in the research, development and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs. The Company has three core assets: a proprietary Bioinformatics assessment tool to match individual (or combination of) cannabinoids against disease targets, a proprietary Biosynthesis cannabinoid manufacturing system to economically produce all 90+ cannabinoids at pharmaceutical-grade (>99.5% purity), and drug development program.
The full research report has a comprehensive overview of InMed's financials, pipeline and potential obstacles READ MORE
(Copy and paste to your browser may be required to view the full report- http://bit.ly/2kA730w-IMLFF-Analyst)
DISCLOSURE
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email between 09:30 EST to 16:00 EST from Monday through Friday at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
SOURCE: Traders News Source
ReleaseID: 455285
